Alliancebernstein L.P. Summit Therapeutics Inc. Transaction History
Alliancebernstein L.P.
- $290 Billion
- Q2 2025
A detailed history of Alliancebernstein L.P. transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Alliancebernstein L.P. holds 17,501 shares of SMMT stock, worth $327,443. This represents 0.0% of its overall portfolio holdings.
Number of Shares
17,501
Previous 92,730
81.13%
Holding current value
$327,443
Previous $1.79 Million
79.19%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding SMMT
# of Institutions
270Shares Held
90.8MCall Options Held
4.71MPut Options Held
3.17M-
Baker Bros. Advisors LP New York, NY33.7MShares$631 Million7.27% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.67MShares$162 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$148 Million0.0% of portfolio
-
State Street Corp Boston, MA4.02MShares$75.2 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.91MShares$73.1 Million0.01% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $3.76B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...